Phylogica granted EU Phylomer patent

Phylogica (ASX:PYC) has been granted a European patent covering its Phylomer peptides that target ischemic conditions.

The patent covers Phylomer peptides targeting the AP-1 pathway, a mediator of lung inflammation and cell death in multiple diseases.

The patent extends to any use of the Phylomers to treat ischemic conditions including stroke, traumatic brain injury and acute respiratory distress syndrome (ARDS).

The peptides covered by the European patent are used to help reduce collateral damage to tissue caused by ischemia - or insufficient blood supply - and by blood returning to the vessel or organ.

Phylogica CEO Dr Paul Watt said the patent “provides further validation of the biological activity of Phylomers against intracellular targets ... not tractable with conventional drugs”.

Phylogica last month was awarded a wide-reaching Australian patent protecting its Phylomer library of peptides as a composition of matter.

The company uses its Phylomer library to provide drug discovery services to the pharmaceutical industry. Major partners include Pfizer, Genentech,  MedImmune and Janssen.

Phylogica shares were trading unchanged at $0.018 as of around 3 pm on Wednesday.